文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

泌尿系统癌症的小干扰RNA递送策略概述

An Overview of siRNA Delivery Strategies for Urological Cancers.

作者信息

Halib Nadia, Pavan Nicola, Trombetta Carlo, Dapas Barbara, Farra Rossella, Scaggiante Bruna, Grassi Mario, Grassi Gabriele

机构信息

Department of Basic Sciences & Oral Biology, Faculty of Dentistry, Universiti Sains Islam Malaysia, Kuala Lumpur 55100, Malaysia.

Urology Clinic, Department of Medical, Surgical and Health Science, University of Trieste, I-34149 Trieste, Italy.

出版信息

Pharmaceutics. 2022 Mar 27;14(4):718. doi: 10.3390/pharmaceutics14040718.


DOI:10.3390/pharmaceutics14040718
PMID:35456552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9030829/
Abstract

The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers.

摘要

近年来,泌尿生殖系统癌症的治疗有了显著改善。然而,对于这些癌症的晚期阶段和/或那些产生耐药性的癌症,需要开发新的治疗选择。在创新策略中,使用小干扰RNA(siRNA)似乎具有很大的治疗价值。siRNA是双链RNA分子,几乎可以特异性靶向任何病理基因的mRNA。因此,siRNA对包括泌尿生殖系统癌症在内的人类疾病具有巨大的治疗潜力。然而,siRNA在生物环境中的脆弱性促使人们开发合适的递送系统来保护它们。因此,确保siRNA在保持结构和功能完整性的同时到达其深部组织靶点是主要挑战之一。为了实现这一目标,基于siRNA的疗法需要开发精细的、量身定制的递送系统。聚合物纳米颗粒、脂质纳米颗粒、纳米气泡和磁性纳米颗粒是最近为满足这一需求而研究的纳米递送系统。在这篇综述中,在介绍泌尿生殖系统肿瘤的主要特征之后,我们描述了siRNA的特性以及为泌尿外科应用开发的代表性递送系统;报道的例子根据不同的递送材料和不同的泌尿生殖系统癌症进行了细分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/fbb4d9b0fd9a/pharmaceutics-14-00718-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/bd524644d6c2/pharmaceutics-14-00718-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/71ac61fefea6/pharmaceutics-14-00718-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/ba57feaa091d/pharmaceutics-14-00718-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/79e3029d4f73/pharmaceutics-14-00718-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/fbb4d9b0fd9a/pharmaceutics-14-00718-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/bd524644d6c2/pharmaceutics-14-00718-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/71ac61fefea6/pharmaceutics-14-00718-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/ba57feaa091d/pharmaceutics-14-00718-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/79e3029d4f73/pharmaceutics-14-00718-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0af2/9030829/fbb4d9b0fd9a/pharmaceutics-14-00718-g005.jpg

相似文献

[1]
An Overview of siRNA Delivery Strategies for Urological Cancers.

Pharmaceutics. 2022-3-27

[2]
Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors.

Pharmaceuticals (Basel). 2022-10-20

[3]
Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer.

Bioengineering (Basel). 2020-8-10

[4]
Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.

Expert Opin Drug Deliv. 2017-6

[5]
Strategies for Delivery of siRNAs to Ovarian Cancer Cells.

Pharmaceutics. 2019-10-22

[6]
Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles.

Nanomedicine (Lond). 2010-9

[7]
Strategies for in vivo delivery of siRNAs: recent progress.

BioDrugs. 2010-6

[8]
Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.

Adv Healthc Mater. 2021-3

[9]
Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.

Cells. 2021-11-29

[10]
Significance and applications of nanoparticles in siRNA delivery for cancer therapy.

Expert Rev Clin Pharmacol. 2012-7

引用本文的文献

[1]
A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System.

Int J Nanomedicine. 2024-12-17

[2]
Overcoming Multidrug Resistance by Base-Editing-Induced Codon Mutation.

ACS Pharmacol Transl Sci. 2023-4-25

[3]
Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors.

Pharmaceuticals (Basel). 2022-10-20

[4]
[Opportunities and Challenges of RNA Interference Therapeutics in Oncology].

Zhongguo Fei Ai Za Zhi. 2022-7-20

本文引用的文献

[1]
Small interfering RNA targeting N-cadherin regulates cell proliferation and migration in enzalutamide-resistant prostate cancer.

Oncol Lett. 2022-3

[2]
Effects of gene silencing on cell cycle and apoptosis in the metastatic renal carcinoma cell line ACHN.

J Int Med Res. 2022-2

[3]
Knocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survival.

Mol Biomed. 2021-10-10

[4]
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.

Eur Urol Oncol. 2021-12

[5]
Development of purified glycogen derivatives as siRNA nanovectors.

Int J Pharm. 2021-10-25

[6]
Clinical Review on the Management of Metastatic Renal Cell Carcinoma.

JCO Oncol Pract. 2022-3

[7]
Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.

Nat Commun. 2021-9-7

[8]
Bladder Cancer: Current Challenges and Future Directions.

Medicina (Kaunas). 2021-7-24

[9]
Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment.

Pharmaceutics. 2021-7-2

[10]
Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancer.

J Nanobiotechnology. 2021-6-23

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索